SCHEMBL6318360

SCHEMBL6318360

Cc1ccsc1-c1noc(N)c1C(=O)NCCCc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.57
TSHR P16473 1/20 0.54
SMN1; SMN2 Q16637 4/20 0.46
HPGD P15428 3/20 0.46
NPC1 O15118 5/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
FAAH O00519 1/20 0.45
POLB P06746 3/20 0.45
GAA P10253 2/20 0.44
KDM4E B2RXH2 2/20 0.44
MAPT P10636 2/20 0.44
S1PR2 O95136 1/20 0.44
ALDH1A1 P00352 1/20 0.44
HTT P42858 1/20 0.44
BLM P54132 1/20 0.44
ATM Q13315 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6315241 0.97 L3MBTL1 (0.53) L3MBTL1TSHRSMN1; SMN2HPGDNPC1
SCHEMBL6318335 0.94 NPC1 (0.50) L3MBTL1TSHRSMN1; SMN2NPC1FAAH
SCHEMBL6318418 0.88 POLB (0.53) TSHRSMN1; SMN2NPC1CYP1A2CYP2C19
SCHEMBL6324184 0.86 ALDH1A1 (0.44) L3MBTL1TSHRSMN1; SMN2HPGDNPC1
SCHEMBL6317656 0.85 GAA (0.42) L3MBTL1SMN1; SMN2HPGDNPC1CYP1A2
SCHEMBL6316236 0.85 GAA (0.41) L3MBTL1SMN1; SMN2HPGDCYP1A2CYP2C9
SCHEMBL6317489 0.85 GAA (0.41) L3MBTL1SMN1; SMN2HPGDCYP1A2CYP2C9
SCHEMBL6324005 0.85 GAA (0.41) L3MBTL1SMN1; SMN2HPGDCYP1A2CYP2C9
SCHEMBL6317742 0.84 ALDH1A1 (0.47) SMN1; SMN2HPGDCYP2C9CYP2C19POLB
SCHEMBL6318930 0.84 POLB (0.39) L3MBTL1TSHRSMN1; SMN2HPGDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
CN-1549714-A Aminoisoxazole derivatives active as kinase inhibitors 2004-11-24 CN claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 L3MBTL1 4176/4885TSHR 3971/4885SMN1; SMN2 2766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.